header banner
Coronavirus

Pfizer's COVID-19 vaccine trial data shows long-term efficacy in adolescents

Nov 23: Pfizer Inc (PFE.N) said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.
By Reuters

Nov 23: Pfizer Inc (PFE.N) said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.


A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said.


Related story

Enrollment for efficacy trial of COVID-19 vaccine begins


The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.


Pfizer and BioNTech (22UAy.DE) will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above.


The vaccine was authorized for emergency use in people aged 12-15 years by the U.S. Food & Drug Administration in May, and granted full approval for use in people aged 16 and above in August.

Related Stories
SOCIETY

Enrollment begins for Sanofi and GSK Phase 3 effic...

Latest Updates

First human trial of AstraZeneca COVID-19 vaccine...

WORLD

India's COVID vaccine wins over some sceptics afte...

OPINION

Curing corona

My City

Coronavirus: Are you suffering from 'Medium COVID'...